Transdermal delivery is used to administer drugs via the skin, which is the human body’s largest organ. Transdermal drug delivery represents a promising alternative to oral, intravascular, subcutaneous and transmucosal routes. Administering medicine through gels, patches and creams is one of the most frequent and effective alternatives to oral delivery, the most common way to take a drug.
This special report focuses on the market leaders for transdermal medicine as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of transdermal medicine prescription-drug developers and marketers is included.
Additionally provided in this report is a listing of transdermal medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the transdermal field.